Comparison over time between both clusters in the DESIR completers cohort: linear mixed-effect analyses
| Variable (range) . | Beta estimate (Cluster B vs A)a . | 95% CI of beta estimate . | Corrected P* . |
|---|---|---|---|
| Peripheral manifestations: | |||
| Peripheral arthralgia: | |||
| At least one tender joint at the time of the visit | 1.60 | 1.24, 1.96 | <0.001 |
| Number of tender joints | 2.87 | 2.22, 3.53 | <0.001 |
| Arthritis: | |||
| At least one arthritis at the time of the visit | 1.11 | 0.64, 1.57 | <0.001 |
| Number of arthritis at the time of the visit | 0.13 | 0.07, 0.19 | <0.001 |
| Peripheral enthesitis: | |||
| MASES >0 at the time of the visit | 1.46 | 1.04, 1.88 | <0.001 |
| MASES at the time of the visit (0–13) | 1.49 | 1.10, 1.88 | <0.001 |
| Extra-articular manifestations: | |||
| Uveitis, at least one episode since the last visit | 0.32 | –0.44, 1.08 | >0.99 |
| Psoriasis, at the time of the visit | 0.16 | –0.61, 0.94 | >0.99 |
| IBD, diagnosis since the last visit | 0.55 | –0.28, 1.39 | >0.99 |
| Disease activity: | |||
| BASDAI (0–100) | 8.48 | 5.59, 11.37 | <0.001 |
| ASDAS-CRP | 0.23 | 0.11, 0.35 | <0.001 |
| Functional outcome/Patient-reported outcome: | |||
| BASFI (0–100) | 7.60 | 4.49, 10.72 | <0.001 |
| HAQ-S (0–3) | 0.25 | 0.18, 0.33 | <0.001 |
| BASG (0–10) | 1.08 | 0.62, 1.55 | <0.001 |
| ASQoL (0–18) | 2.10 | 1.33, 2.87 | <0.001 |
| SF36—PCS | –3.64 | –4.91, –2.37 | <0.001 |
| SF36—MCS | –2.26 | –3.67, –0.84 | 0.05 |
| Biological outcome: | |||
| CRP (mg/l) | –0.18 | –1.24, 0.88 | 0.70 |
| ESR (mm) | –0.31 | –1.88, 1.26 | 0.70 |
| Imaging outcome: | |||
| Radiographic sacroiliitisb | –0.97 | –2.09, 0.14 | 0.001 |
| Total MSASSS (0–72) | 0.27 | –0.27, 0.8 | 0.30 |
| MRI sacroiliitisc | –1.05 | –1.81, –0.28 | 0.04 |
| SPARCC sacroiliac score (0–72) | –1.88 | –3.04, –0.73 | 0.05 |
| SPARCC spine score (0–108) | –1.38 | –2.29, –0.47 | 0.09 |
| PDUS enthesitisd | 0.21 | –0.36, 0.77 | >0.99 |
| Treatment: | |||
| NSAID (at the time of the visit) | –0.08 | –0.52, 0.35 | >0.99 |
| ASAS NSAID score (last 6 months) | 5.84 | 0.73, 10.94 | 0.70 |
| ASAS NSAID score (last week) | 6.55 | 1.39, 11.72 | 0.40 |
| Analgesics use (at the time of the visit) | 1.22 | 0.74, 1.69 | <0.001 |
| Conventional DMARD (at the time of the visit) | 2.26 | 1.27, 3.25 | <0.001 |
| TNF blocker (at the time of the visit) | 1.55 | 0.49, 2.62 | <0.001 |
| Variable (range) . | Beta estimate (Cluster B vs A)a . | 95% CI of beta estimate . | Corrected P* . |
|---|---|---|---|
| Peripheral manifestations: | |||
| Peripheral arthralgia: | |||
| At least one tender joint at the time of the visit | 1.60 | 1.24, 1.96 | <0.001 |
| Number of tender joints | 2.87 | 2.22, 3.53 | <0.001 |
| Arthritis: | |||
| At least one arthritis at the time of the visit | 1.11 | 0.64, 1.57 | <0.001 |
| Number of arthritis at the time of the visit | 0.13 | 0.07, 0.19 | <0.001 |
| Peripheral enthesitis: | |||
| MASES >0 at the time of the visit | 1.46 | 1.04, 1.88 | <0.001 |
| MASES at the time of the visit (0–13) | 1.49 | 1.10, 1.88 | <0.001 |
| Extra-articular manifestations: | |||
| Uveitis, at least one episode since the last visit | 0.32 | –0.44, 1.08 | >0.99 |
| Psoriasis, at the time of the visit | 0.16 | –0.61, 0.94 | >0.99 |
| IBD, diagnosis since the last visit | 0.55 | –0.28, 1.39 | >0.99 |
| Disease activity: | |||
| BASDAI (0–100) | 8.48 | 5.59, 11.37 | <0.001 |
| ASDAS-CRP | 0.23 | 0.11, 0.35 | <0.001 |
| Functional outcome/Patient-reported outcome: | |||
| BASFI (0–100) | 7.60 | 4.49, 10.72 | <0.001 |
| HAQ-S (0–3) | 0.25 | 0.18, 0.33 | <0.001 |
| BASG (0–10) | 1.08 | 0.62, 1.55 | <0.001 |
| ASQoL (0–18) | 2.10 | 1.33, 2.87 | <0.001 |
| SF36—PCS | –3.64 | –4.91, –2.37 | <0.001 |
| SF36—MCS | –2.26 | –3.67, –0.84 | 0.05 |
| Biological outcome: | |||
| CRP (mg/l) | –0.18 | –1.24, 0.88 | 0.70 |
| ESR (mm) | –0.31 | –1.88, 1.26 | 0.70 |
| Imaging outcome: | |||
| Radiographic sacroiliitisb | –0.97 | –2.09, 0.14 | 0.001 |
| Total MSASSS (0–72) | 0.27 | –0.27, 0.8 | 0.30 |
| MRI sacroiliitisc | –1.05 | –1.81, –0.28 | 0.04 |
| SPARCC sacroiliac score (0–72) | –1.88 | –3.04, –0.73 | 0.05 |
| SPARCC spine score (0–108) | –1.38 | –2.29, –0.47 | 0.09 |
| PDUS enthesitisd | 0.21 | –0.36, 0.77 | >0.99 |
| Treatment: | |||
| NSAID (at the time of the visit) | –0.08 | –0.52, 0.35 | >0.99 |
| ASAS NSAID score (last 6 months) | 5.84 | 0.73, 10.94 | 0.70 |
| ASAS NSAID score (last week) | 6.55 | 1.39, 11.72 | 0.40 |
| Analgesics use (at the time of the visit) | 1.22 | 0.74, 1.69 | <0.001 |
| Conventional DMARD (at the time of the visit) | 2.26 | 1.27, 3.25 | <0.001 |
| TNF blocker (at the time of the visit) | 1.55 | 0.49, 2.62 | <0.001 |
Beta estimates are given for clusters with cluster A as reference (i.e. if beta >0, the score/frequency is higher in cluster B than in cluster A).
Refers to radiographic sacroiliitis ≥ grade II bilateral or grade III unilateral.
As defined by ASAS classification criteria for axial spondyloarthritis.
At least one vascularized enthesitis detected using PDUS.
After Holm–Bonferroni correction.
95% CI: 95% confidence interval; ASAS: Assessment of SpondyloArthritis international Society; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score using CRP; ASQoL: Ankylosing Spondylitis Quality of Life Questionnaire; BASG: Bath Ankylosing Spondylitis Global Score; HAQ-S: HAQ Disability Index for the Spondyloarthropathies; MASES: Mases Ankylosing Spondylitis Enthesitis Score; MCS: mental component summary; MSASSS: Modified stoke ankylosing spondylitis spinal score; PCS: physical component summary; PDUS: power Doppler ultrasound; SF36: 36-Item Short Form Survey; SPARCC: Spondyloarthritis Research Consortium of Canada.
Comparison over time between both clusters in the DESIR completers cohort: linear mixed-effect analyses
| Variable (range) . | Beta estimate (Cluster B vs A)a . | 95% CI of beta estimate . | Corrected P* . |
|---|---|---|---|
| Peripheral manifestations: | |||
| Peripheral arthralgia: | |||
| At least one tender joint at the time of the visit | 1.60 | 1.24, 1.96 | <0.001 |
| Number of tender joints | 2.87 | 2.22, 3.53 | <0.001 |
| Arthritis: | |||
| At least one arthritis at the time of the visit | 1.11 | 0.64, 1.57 | <0.001 |
| Number of arthritis at the time of the visit | 0.13 | 0.07, 0.19 | <0.001 |
| Peripheral enthesitis: | |||
| MASES >0 at the time of the visit | 1.46 | 1.04, 1.88 | <0.001 |
| MASES at the time of the visit (0–13) | 1.49 | 1.10, 1.88 | <0.001 |
| Extra-articular manifestations: | |||
| Uveitis, at least one episode since the last visit | 0.32 | –0.44, 1.08 | >0.99 |
| Psoriasis, at the time of the visit | 0.16 | –0.61, 0.94 | >0.99 |
| IBD, diagnosis since the last visit | 0.55 | –0.28, 1.39 | >0.99 |
| Disease activity: | |||
| BASDAI (0–100) | 8.48 | 5.59, 11.37 | <0.001 |
| ASDAS-CRP | 0.23 | 0.11, 0.35 | <0.001 |
| Functional outcome/Patient-reported outcome: | |||
| BASFI (0–100) | 7.60 | 4.49, 10.72 | <0.001 |
| HAQ-S (0–3) | 0.25 | 0.18, 0.33 | <0.001 |
| BASG (0–10) | 1.08 | 0.62, 1.55 | <0.001 |
| ASQoL (0–18) | 2.10 | 1.33, 2.87 | <0.001 |
| SF36—PCS | –3.64 | –4.91, –2.37 | <0.001 |
| SF36—MCS | –2.26 | –3.67, –0.84 | 0.05 |
| Biological outcome: | |||
| CRP (mg/l) | –0.18 | –1.24, 0.88 | 0.70 |
| ESR (mm) | –0.31 | –1.88, 1.26 | 0.70 |
| Imaging outcome: | |||
| Radiographic sacroiliitisb | –0.97 | –2.09, 0.14 | 0.001 |
| Total MSASSS (0–72) | 0.27 | –0.27, 0.8 | 0.30 |
| MRI sacroiliitisc | –1.05 | –1.81, –0.28 | 0.04 |
| SPARCC sacroiliac score (0–72) | –1.88 | –3.04, –0.73 | 0.05 |
| SPARCC spine score (0–108) | –1.38 | –2.29, –0.47 | 0.09 |
| PDUS enthesitisd | 0.21 | –0.36, 0.77 | >0.99 |
| Treatment: | |||
| NSAID (at the time of the visit) | –0.08 | –0.52, 0.35 | >0.99 |
| ASAS NSAID score (last 6 months) | 5.84 | 0.73, 10.94 | 0.70 |
| ASAS NSAID score (last week) | 6.55 | 1.39, 11.72 | 0.40 |
| Analgesics use (at the time of the visit) | 1.22 | 0.74, 1.69 | <0.001 |
| Conventional DMARD (at the time of the visit) | 2.26 | 1.27, 3.25 | <0.001 |
| TNF blocker (at the time of the visit) | 1.55 | 0.49, 2.62 | <0.001 |
| Variable (range) . | Beta estimate (Cluster B vs A)a . | 95% CI of beta estimate . | Corrected P* . |
|---|---|---|---|
| Peripheral manifestations: | |||
| Peripheral arthralgia: | |||
| At least one tender joint at the time of the visit | 1.60 | 1.24, 1.96 | <0.001 |
| Number of tender joints | 2.87 | 2.22, 3.53 | <0.001 |
| Arthritis: | |||
| At least one arthritis at the time of the visit | 1.11 | 0.64, 1.57 | <0.001 |
| Number of arthritis at the time of the visit | 0.13 | 0.07, 0.19 | <0.001 |
| Peripheral enthesitis: | |||
| MASES >0 at the time of the visit | 1.46 | 1.04, 1.88 | <0.001 |
| MASES at the time of the visit (0–13) | 1.49 | 1.10, 1.88 | <0.001 |
| Extra-articular manifestations: | |||
| Uveitis, at least one episode since the last visit | 0.32 | –0.44, 1.08 | >0.99 |
| Psoriasis, at the time of the visit | 0.16 | –0.61, 0.94 | >0.99 |
| IBD, diagnosis since the last visit | 0.55 | –0.28, 1.39 | >0.99 |
| Disease activity: | |||
| BASDAI (0–100) | 8.48 | 5.59, 11.37 | <0.001 |
| ASDAS-CRP | 0.23 | 0.11, 0.35 | <0.001 |
| Functional outcome/Patient-reported outcome: | |||
| BASFI (0–100) | 7.60 | 4.49, 10.72 | <0.001 |
| HAQ-S (0–3) | 0.25 | 0.18, 0.33 | <0.001 |
| BASG (0–10) | 1.08 | 0.62, 1.55 | <0.001 |
| ASQoL (0–18) | 2.10 | 1.33, 2.87 | <0.001 |
| SF36—PCS | –3.64 | –4.91, –2.37 | <0.001 |
| SF36—MCS | –2.26 | –3.67, –0.84 | 0.05 |
| Biological outcome: | |||
| CRP (mg/l) | –0.18 | –1.24, 0.88 | 0.70 |
| ESR (mm) | –0.31 | –1.88, 1.26 | 0.70 |
| Imaging outcome: | |||
| Radiographic sacroiliitisb | –0.97 | –2.09, 0.14 | 0.001 |
| Total MSASSS (0–72) | 0.27 | –0.27, 0.8 | 0.30 |
| MRI sacroiliitisc | –1.05 | –1.81, –0.28 | 0.04 |
| SPARCC sacroiliac score (0–72) | –1.88 | –3.04, –0.73 | 0.05 |
| SPARCC spine score (0–108) | –1.38 | –2.29, –0.47 | 0.09 |
| PDUS enthesitisd | 0.21 | –0.36, 0.77 | >0.99 |
| Treatment: | |||
| NSAID (at the time of the visit) | –0.08 | –0.52, 0.35 | >0.99 |
| ASAS NSAID score (last 6 months) | 5.84 | 0.73, 10.94 | 0.70 |
| ASAS NSAID score (last week) | 6.55 | 1.39, 11.72 | 0.40 |
| Analgesics use (at the time of the visit) | 1.22 | 0.74, 1.69 | <0.001 |
| Conventional DMARD (at the time of the visit) | 2.26 | 1.27, 3.25 | <0.001 |
| TNF blocker (at the time of the visit) | 1.55 | 0.49, 2.62 | <0.001 |
Beta estimates are given for clusters with cluster A as reference (i.e. if beta >0, the score/frequency is higher in cluster B than in cluster A).
Refers to radiographic sacroiliitis ≥ grade II bilateral or grade III unilateral.
As defined by ASAS classification criteria for axial spondyloarthritis.
At least one vascularized enthesitis detected using PDUS.
After Holm–Bonferroni correction.
95% CI: 95% confidence interval; ASAS: Assessment of SpondyloArthritis international Society; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score using CRP; ASQoL: Ankylosing Spondylitis Quality of Life Questionnaire; BASG: Bath Ankylosing Spondylitis Global Score; HAQ-S: HAQ Disability Index for the Spondyloarthropathies; MASES: Mases Ankylosing Spondylitis Enthesitis Score; MCS: mental component summary; MSASSS: Modified stoke ankylosing spondylitis spinal score; PCS: physical component summary; PDUS: power Doppler ultrasound; SF36: 36-Item Short Form Survey; SPARCC: Spondyloarthritis Research Consortium of Canada.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
